Pharmaceutical News

RSS

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Eli Lilly Canada announced today that Health Canada has approved Cymbalta for the management of chronic low back pain.

30 Apr 2011

FDA approves Abbott's AndroGel for hypogonadism treatment in men

Abbott announced today that the U.S. Food and Drug Administration has approved AndroGel 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.

30 Apr 2011

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration on April 29, 2011, for the use of FUSILEV in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

30 Apr 2011

New study identifies less invasive therapy for ACE inhibitor side-effects

A new Henry Ford Hospital study takes a closer look at one of the lesser known, but potential most serious side-effects of ACE inhibitor use - facial, tongue and airway swelling - and identifies a successful and less invasive course of treatment.

29 Apr 2011

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Vertex Pharmaceuticals Incorporated announced that the Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously to recommend FDA approval of telaprevir for people with genotype 1 chronic hepatitis C.

29 Apr 2011

Avastin, Lucentis are equally effective for age-related macular degeneration treatment

Age-related macular degeneration, a disease that damages the retina and can destroy central vision, affects approximately 1.6 million Americans. For the past five years, there has been active debate over treatment options for AMD patients because ophthalmologists have not had accurate data regarding the true efficacy of the most commonly used medication.

29 Apr 2011

Flu vaccination lowers kidney transplant recipients' risk of organ loss and death

Getting vaccinated against the flu lowers kidney transplant recipients' risk of organ loss and death, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

29 Apr 2011

CTSN focuses on new prairie vole model for autism treatment

Researchers at the Center for Translational Social Neuroscience at Emory University are focusing on prairie voles as a new model to screen the effectiveness of drugs to treat autism.

29 Apr 2011

Study finds low pediatric flu vaccination acceptance rates in Atlanta

A study of H1N1 and seasonal influenza vaccination in a sample of black and Hispanic children in Atlanta found a low rate of vaccine acceptance among parents and caregivers.

29 Apr 2011

Bayer expands sponsorship agreement with World Federation of Hemophilia

Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia are announcing a three-year extension of Bayer's sponsorship agreement with WFH.

29 Apr 2011

UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the company's proposed research collaboration with the University of Massachusetts Medical School has been selected for Cooperative Research Matching Grant funding by the Massachusetts Life Sciences Center.

29 Apr 2011

Researchers report Avastin is effective as Lucentis for AMD treatment

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration, is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD.

29 Apr 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.

29 Apr 2011

Antibiotics may serve as effective treatment for appendicitis than surgery

Antibiotics rather than surgery may be the better treatment for cases of appendicitis in which the appendix hasn't burst, according to a new study.

29 Apr 2011

Longer looks: Autism researcher's legacy; methadone for prisoners

Andrew Wakefield has become one of the most reviled doctors of his generation, blamed directly and indirectly, depending on the accuser, for irresponsibly starting a panic with tragic repercussions: vaccination rates so low that childhood diseases once all but eradicated here —whooping cough and measles, among them — have re-emerged, endangering young lives. And yet here he was in Texas, post-career-apocalypse, calmly discussing his work, and a crowd of around 250 people showed up to listen.

29 Apr 2011

Drug subsidy issues out of PBS’ hands - almost

According to Health Minister Nicola Roxon, expensive drugs have never been automatically listed for subsidy and they can't be now when the government controlling expenses. She added that federal Labor has to balance competing priorities in health and every other department.

29 Apr 2011

Celanese EVA Performance Polymers, PSI partner to develop drug-eluting devices

Particle Sciences Inc., a leading pharmaceutical CRO, and Celanese EVA Performance Polymers, a leading supplier of ethylene vinyl acetate into pharmaceutical applications, are working together to streamline the development of drug-eluting devices.

29 Apr 2011

Ramipril can effectively reduce risk of ESRD in obese patients

The angiotensin-converting enzyme inhibitor drug, ramipril, is particularly effective in lowering the risk of end-stage renal disease in obese patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

29 Apr 2011

UIC receives federal contract to develop antibiotics against three bacterial infections

Researchers at the University of Illinois at Chicago's Center for Pharmaceutical Biotechnology have been awarded a federal contract for up to $13.8 million to develop antibiotics to treat anthrax, tularemia and plague.

28 Apr 2011

LEO Pharma introduces new Taclonex website for plaque psoriasis treatment

LEO Pharma Inc., a wholly-owned US subsidiary of LEO Pharma A/S, makers of Taclonex brand products, today announced the launch of an enhanced and expanded website at www.taclonex.com.

28 Apr 2011